Sitafloxacin hydrate
Based on 6 publication(s) in Google Scholar
Sitafloxacin (DU6859a) hydrate is an orally active fluoroquinolone antibiotic (antibiotic) with in vitro activity against a wide range of Gram-positive and -negative bacteria, including anaerobic bacteria, as well as atypical pathogens. Sitafloxacin is used in the study of respiratory tract infections and urinary tract infections.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 163253-35-8
- Formula: C19H18ClF2N3O3.3/2H2O
- Molecular Weight:436.84
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Sitafloxacin hydrate
MoreAll Antibiotic Isoforms
More
Biological Activity
|
Quinolone |
The minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and mutation prevention concentration (MPC) of Sitafloxacin hydrate against Mycobacterium avium are 2 mg/L, 2 mg/L and 45 mg/L, respectively[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 163253-35-8
-
Appearance Solid
-
Molecular Weight 436.84
-
Formula C19H18ClF2N3O3.3/2H2O
-
Color White to off-white
-
SMILES
N[C@H]1C2(CC2)CN(C(C(Cl)=C3N([C@H]4[C@@H](F)C4)C=C(C(O)=O)C5=O)=C(C=C35)F)C1.[1.5 H2O]
-
Synonyms
DU6859a hydrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Antimicrob Resist Infect Control
Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. [Abstract]2019 Feb 15:8:40. PMID: 30815255 -
Toxicol Sci
In vitro and preclinical assessment of drug interactions between fluoroquinolones and a nonsteroidal antiinflammatory drug predicting risk of seizure. [Abstract]2026 Mar 25:kfag039. PMID: 41883118 -
Infect Drug Resist
Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance. [Abstract]2019 Jan 31:12:345-358. PMID: 30774400 -
Curr Microbiol
Repurposing Sitafloxacin, Prulifloxacin, Tosufloxacin, and Sisomicin as Antimicrobials Against Biofilm and Persister Cells of Pseudomonas aeruginosa. [Abstract]2021 Dec 14;79(1):12. PMID: 34905092 -
PLoS One
Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic. [Abstract]2019 Mar 27;14(3):e0213868. PMID: 30917150 -
Solvent & Solubility
DMSO : 8.9 mg/mL (20.37 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.76 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.76 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Anderson, D.L., Sitafloxacin hydrate for bacterial infections. Drugs Today (Barc), 2008. 44(7): p. 489-501. [Content Brief]
[2]. Keating, et al. Sitafloxacin: in bacterial infections. Drugs, 2011. 71(6): p. 731-44. [Content Brief]
[3]. Surapee Tiengrim, et al. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections. J Med Assoc Thai. 2012 Feb;95 Suppl 2:S6-17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2892 mL | 11.4458 mL | 22.8917 mL | 57.2292 mL |
| 5 mM | 0.4578 mL | 2.2892 mL | 4.5783 mL | 11.4458 mL | |
| 10 mM | 0.2289 mL | 1.1446 mL | 2.2892 mL | 5.7229 mL | |
| 15 mM | 0.1526 mL | 0.7631 mL | 1.5261 mL | 3.8153 mL | |
| 20 mM | 0.1145 mL | 0.5723 mL | 1.1446 mL | 2.8615 mL |
Sitafloxacin hydrate Related Classifications
HY-B0395C Related Classifications
Powered by Bioz